Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer-Reference-Cited by-同舟云学术

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

Published:2010-09-08 Issue:48 Volume:2 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Wallin Jeffrey J.¹,Guan Jane¹,Prior Wei Wei¹,Edgar Kyle A.¹,Kassees Robert¹,Sampath Deepak¹,Belvin Marcia¹,Friedman Lori S.¹

Affiliation:

1. Cancer Signaling, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

Abstract

Akt phosphorylation in response to DNA damage predicts the sensitivity of cancer cells to combinations of a PI3K inhibitor and the replication inhibitor doxorubicin.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference45 articles.

1. Oncogenic PI3K deregulates transcription and translation

2. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

3. Activation of Akt Predicts Poor Outcome in Neuroblastoma

4. Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells

5. Increased expression of pAKT is associated with radiation resistance in cervical cancer

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT;Cancer Research;2024-06-20

2. DNA tetrahedral nanostructures for the biomedical application and spatial orientation of biomolecules;Bioactive Materials;2024-03

3. Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis;International Journal of Molecular Sciences;2023-09-13

4. Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer;The Oncologist;2023-04-06

5. Quatramer™ mediated co-delivery of PI3-Kδ/HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer;European Journal of Pharmaceutics and Biopharmaceutics;2022-10